A machine learning approach for multimodal data fusion for survival prediction in cancer patients.
Nikolaou N. et al, (2025), NPJ Precis Oncol, 9
Towards a survival risk prediction model for metastatic NSCLC patients on durvalumab using whole-lung CT radiomics.
Patwardhan KA. et al, (2024), Front Immunol, 15
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept, randomized double-blind placebo-controlled trial
TOMLINSON J., (2023), Nature Communications
Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents.
Hazlehurst JM. et al, (2022), Metabol Open, 14
AKR1D1 knockout mice develop a sex-dependent metabolic phenotype.
Gathercole LL. et al, (2022), J Endocrinol, 253, 97 - 113
Akr1d1-/-mice have a sexually dimorphic metabolic phenotype with reduced fat mass, increased insulin sensitivity and hypertriglyceridemia in males
Gathercole LL. et al, (2021), bioRxiv, 2021.02.02.429227 - 2021.02.02.429227
Differential activity and expression of human 5β-reductase (AKR1D1) splice variants
Appanna N. et al, (2021), Journal of Molecular Endocrinology
The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies
NIKOLAOU N. et al, (2021), The Journal of Steroid Biochemistry and Molecular Biology, 105808 - 105808
The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1
Barnard L. et al, (2020), The Journal of Steroid Biochemistry and Molecular Biology, 105724 - 105724
Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids
Othonos N. et al, (2020), The Journal of Clinical Endocrinology & Metabolism
Differential activity and expression of human 5β-reductase (AKR1D1) splice variants
Appanna N. et al, (2020), bioRxiv
Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo.
Nikolaou N. et al, (2020), J Endocrinol
5[beta]-reductase (AKR1D1) isoforms differentially regulate natural and synthetic glucocorticoid clearance and glucocorticoid receptor activation in vitro
Appanna N. et al, (2019), Endocrine Abstracts
5[beta]-reductase (AKR1D1) is downregulated in patients with non-alcoholic fatty liver disease and protects against hepatocellular carcinoma cell proliferation in vitro
Nikolaou N. et al, (2019), Endocrine Abstracts
AKR1D1 (5[beta]-reductase) deletion drives hepatic inflammation, fibrosis and tumour development in vivo
Harris S. et al, (2019), Endocrine Abstracts
Intestinal injury and evidence of increased gut permeability in female AKR1D1 knockout mice
Arvaniti A. et al, (2019), Endocrine Abstracts
AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease
Nikolaou N. et al, (2019), Metabolism, 153947 - 153947
AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells.
Nikolaou N. et al, (2019), J Steroid Biochem Mol Biol, 189, 218 - 227
Differential regulation of 5[beta]-reductase (AKR1D1) expression and activity by glucocorticoids in human and rodent liver
Nikolaou N. et al, (2019), Endocrine Abstracts
5β-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo
Nikolaou N. et al, (2018), Endocrine Abstracts, 59